RETRACTED: Long noncoding RNA TP73-AS1 promotes non-small cell lung cancer progression by competitively sponging miR-449a/EZH2

Zhang, Lin; Fang, Fengqi; He, Xin

doi:10.1016/j.biopha.2018.05.089

Cited by 47 publications

(44 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The increasing vital roles of lncRNAs have been involved in more and more extensive fields, including human tumours, cardiovascular system disorder, or metabolic diseases . In this study, our data concluded that CASC9 was dramatically high‐expressed in glioma tissue and cells, illustrating the pessimistic role of CASC9 in glioma patients.…”

Section: Discussionmentioning

confidence: 52%

“…ns presented no significant difference system disorder, or metabolic diseases. [15][16][17][18][19] In this study, our data axis. 23 HOXA11-AS is significantly up-regulated in glioma tissues and cell lines and its knockdown inhibits glioma cell proliferation, migration and invasion in vitro, and tumour growth in vivo, thereby via ceRNA for miR-214-3p and its direct target EZH2.…”

Section: Discussionmentioning

confidence: 78%

See 1 more Smart Citation

Long noncoding RNA CASC9/miR‐519d/STAT3 positive feedback loop facilitate the glioma tumourigenesis

Liu

Yang

et al. 2018

J Cellular Molecular Medi

View full text Add to dashboard Cite

Emerging evidence have illustrated the vital roles of long noncoding RNAs (lncRNAs) in glioma. Nevertheless, the majority of their roles and mechanisms in gliomagenesis are still largely unclear. In this study, we investigate the roles of lncRNA CASC9 on glioma tumourigenesis and authenticate its potential mechanisms. Results manifested that CASC9 was highly expressed in glioma specimens and cells, moreover, the ectopic overexpression was correlated with glioma patients’ clinic. Functional studies found that siRNA‐mediated CASC9 silencing inhibited the proliferative ability, invasion in vitro, and impaired the tumour growth in vivo. Mechanical studies revealed that miR‐519d both targeted the 3′‐UTR of CASC9 and STAT3 mRNA, which was identified by luciferase reporter assay and RNA immunoprecipitation (RIP). Moreover, chromatin immunoprecipitation (ChIP) and luciferase reporter assay revealed that STAT3, an oncogenic transcription factor, could bind with the promoter of CASC9 and activate its transcriptional level. In conclusion, our results concluded that CASC9 promotes STAT3 expression via sponging miR‐519d, in return, STAT3 activate CASC9 transcription, forming a positive feedback loop of CASC9/miR‐519d/STAT3. The novel finding provides a potential therapeutic target for glioma.

show abstract

Section: Discussionmentioning

confidence: 52%

Section: Discussionmentioning

confidence: 78%

Long noncoding RNA CASC9/miR‐519d/STAT3 positive feedback loop facilitate the glioma tumourigenesis

Liu

Yang

et al. 2018

J Cellular Molecular Medi

View full text Add to dashboard Cite

show abstract

“…Recently, growing evidence indicated that lncRNAs could competitively suppress miRNAs by acting as molecular sponges [15,16]. For instance, lncRNA TP73-AS1 promoted NSCLC cell proliferation, tumour growth and cycle progression by competitively sponging miR-449a [17]. LncRNA FBXL19-AS1 plays oncogenic role in CRC by sponging miR-203 [18].…”

Section: Introductionmentioning

confidence: 99%

Long non-coding RNA LINC00858 promotes cells proliferation, migration and invasion by acting as a ceRNA of miR-22-3p in colorectal cancer

Sha¹,

Chen²,

et al. 2019

Artificial Cells, Nanomedicine, and Biotechnology

View full text Add to dashboard Cite

Though long non-coding RNA LINC00858 (LINC00858) has been shown to be involved in tumours of other tissues, its involvement in colorectal cancer (CRC) is still unknown. We aimed to investigated expression and mechanism LINC00858 in human CRC. In this study, we firstly found that LINC00858 expression was significantly up-regulated in both CRC tissues and cell lines by both online data and RT-PCR assay. Then, clinical assay revealed that high LINC00858 expression was significantly associated with advanced clinical progression and poor prognosis. Multivariate analysis demonstrated that high LINC00858 expression was an independent poor prognostic factor for CRC patients. Moreover, lost-offunction assay indicated that knockdown of LINC00858 suppressed CRC cells proliferation, migration and invasion, and promoted apoptosis. Mechanistically, bioinformatics analysis, dual-luciferase reporter assays, and western blot assays showed that LINC00858 functioned as competing endogenous RNA to repress miR-22-3p, which controlled its downstream target YWHAZ. Then, we suggested that LINC00858 exerted its function through the miR-22-3p/YWHAZ axis. To our knowledge, this is the first report which showed the role of LINC00858 in the progression of CRC. Our findings indicated that LINC00858 played an important role in CRC, and may serve as a novel prognostic factor and therapeutic target.

show abstract

“…Moreover, silencing TP73-AS1 depressed LAD tumor growth and metastasis in vivo. Mechanistically, the molecular pathway TP73-AS1/miR-449a/enhancer of zeste homolog 2 (EZH2) promotes NSCLC tumorigenesis via epigenetic modulation, whereas TP73-AS1 promotes the progression of LAD through the activation of the PI3K/AKT signaling pathway [35,36]. Collectively, TP73-AS1 might be a promising therapeutic and prognostic indicator both for LAD and NSCLC.…”

Section: Lung Cancermentioning

confidence: 99%

Role of long non-coding RNA TP73-AS1 in cancer

2019

View full text Add to dashboard Cite

Cancer incidence rate has increased so much that it is the second leading cause of deaths worldwide after cardiovascular diseases. Sensitive and specific biomarkers are needed for an early diagnosis of cancer and in-time treatment. Recent studies have found that long non-coding RNAs (lncRNAs) participate in cancer tumorigenesis. LncRNA P73 antisense RNA 1T (TP73-AS1), also known as KIAA0495 and p53-dependent apoptosis modulator (PDAM), is located in human chromosomal band 1p36.32 and plays a crucial role in many different carcinomas. This review summarizes current findings on the role of TP73-AS1 and its signaling pathways in various cancers, including glioma, esophageal squamous cell carcinoma (ESCC), hepatocellular carcinoma (HCC), colorectal cancer (CRC), osteosarcoma, gastric cancer (GC), clear cell renal cell carcinoma (ccRCC), breast cancer (BC), bladder cancer, ovarian cancer, cholangiocarcinoma (CCA), lung cancer, and pancreatic cancer. Its aberrant expression generally correlates with clinicopathological characterization of patients. Moreover, TP73-AS1 regulates proliferation, migration, invasion, apoptosis, and chemoresistance cancer mechanisms, both in vivo and in vitro, through different signaling pathways. Therefore, TP73-AS1 may be considered as a marker for diagnosis and prognosis, also as a target for cancer treatment.

show abstract

RETRACTED: Long noncoding RNA TP73-AS1 promotes non-small cell lung cancer progression by competitively sponging miR-449a/EZH2

Cited by 47 publications

References 24 publications

Long noncoding RNA CASC9/miR‐519d/STAT3 positive feedback loop facilitate the glioma tumourigenesis

Long noncoding RNA CASC9/miR‐519d/STAT3 positive feedback loop facilitate the glioma tumourigenesis

Long non-coding RNA LINC00858 promotes cells proliferation, migration and invasion by acting as a ceRNA of miR-22-3p in colorectal cancer

Role of long non-coding RNA TP73-AS1 in cancer

Contact Info

Product

Resources

About